Adeno associated virus (AAV) is a structurally simple single stranded DNA virus. Recombinant adeno-associated virus vector (rAAV) is derived from non pathogenic wild-type adeno-associated virus, which has good safety, wide host cell infectivity, and long in vivo expression time. Currently, the scientific community generally believes that AAV does not cause human diseases and is therefore considered the most promising gene therapy vector.

Recombinant adeno-associated virus (rAAV) has been widely used in gene therapy due to its safety and efficacy. However, in the packaging and clinical process of AAV virus, there are issues such as high shell rate, low integrity, high impurity DNA residue, and potential genome integration risks, which seriously affect the safety and effectiveness of clinical treatment. To this end, GentleGen has launched the AAV high-throughput sequencing safety assessment platform AAV NGSafety™。 This platform utilizes second-generation and third-generation sequencing technology to analyze the purity of AAV virus packaging, the integrity of AAV target sequences, the accuracy of ITR regions, and potential insertion sites of AAV genomes. Its aim is to help customers in gene therapy drug development optimize AAV production processes, characterize potential safety risks of AAV gene therapy vectors, and accelerate the faster and safer delivery of AAV gene therapy drugs to patients.